Wells Fargo’s Cognition Therapeutics CGTX Stock Holding History
Bought
Maintained
Sold
Other funds holding CGTX
C
CM
Wells Fargo's CGTX Position: Q3 2026 in Review
Wells Fargo increased its Cognition Therapeutics (CGTX) stake by 117% in Q3 2026, buying an estimated $3.52K and bringing the position to 6,500 shares worth $6.24K. The position accounts for ﹤0.01% of the portfolio, ranked #6213.
Wells Fargo first reported a position in CGTX in Q4 2021 and has held it in 20 quarters since. The position peaked at $162K in Q2 2022. 78 funds tracked by Wall St. Rank hold CGTX as of Q3 2026.
- Wells Fargo held 6,500 shares of Cognition Therapeutics worth $6.24K as of Q3 2026.
- Wells Fargo bought 3,500 Cognition Therapeutics shares in Q3 2026, an estimated $3.52K.
- Cognition Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q3 2026, its #6213 holding.
- Wells Fargo first reported a position in Cognition Therapeutics in Q4 2021 and has held it in 20 quarters since.
- Wells Fargo's Cognition Therapeutics position peaked at $162K in Q2 2022.
- 78 funds tracked by Wall St. Rank held Cognition Therapeutics as of Q3 2026.
Based on Wells Fargo's 13F filing for Q3 2026, filed 16 Nov 2026.